Latest Industry Insights

The biotech/genetic engineering company Colossal – co-founded in 2021 by renowned geneticist Professor George Church and serial entrepreneur Ben Lamm – announced it has begun a de-extinction project of the thylacine – an Australian marsupial commonly referred to as the “Tasmanian tiger”. Technology Networks interviewed the team to learn more.

Technology Networks recently had the pleasure of speaking to Dr. Philip Empey, to learn more about the Pharmacogenomics Center for Excellence and how it is working to prove the clinical utility of predictive PGx testing.

In this interview with Bryan Kobel, CEO of TC Biopharm, we find out about gamma-delta T-cell therapy, including how it works, its applications and how TC Biopharm developed its pioneering gamma-delta treatment for acute myeloid leukemia.

There is widespread concern about the characteristics of PFAS and its impacts on human health. Can a protein biosensor help in this fight?

To understand how machine learning methods and new software capabilities are helping proteomics researchers gain greater depth in their analyses, Technology Networks recently interviewed Tharan Srikumar, product manager in bioinformatics at Bruker Daltonics.

In this interview, Rolland Carlson, PhD, CEO of Immunexpress, discusses sepsis and the company’s FDA cleared SeptiCyte® RAPID test, as well as a take on the company’s differentiated value and outlook.

Technology Networks spoke to Dr. Cenk Sumen, chief scientific officer of MaxCyte, about their pioneering cell engineering platform.

In this interview, we speak to Alon Ben-Noon, CEO and co-founder of Neurosense Therapeutics to hear about the impact their drug development strategy is having on the ALS field.

This article explores the current state of brain-computer interface technology and some of the ethical considerations associated with its use.

Developing and manufacturing biotherapeutics at scale requires thorough analysis of the active substance’s characteristics to ensure it fulfils both efficacy and safety requirements. Analytical technologies, such as mass spectrometry, are key tools adopted in this process.